Abstract
The concept of treatment emergent suicidality during clinical trials has been a subject of regulatory and research interest, especially since the early 1990s. A key series of analyses have shaped the regulatory environment for expectations of prospective assessment of suicidal ideation and behavior (SIB) in clinical trials. The development of a scale for prospective assessment of these events has been a key priority in order to detect emergent signs during the course of a clinical trial and to assist in patient selection criteria of suicide risk. The maturing regulatory environment and increasing evolution in thinking on definitions of SIB have underpinned significant changes in the main assessment scale, the Columbia Suicide Severity Rating Scale (C-SSRS), as well as in the standard adopted by the FDA for coding, summarizing, and analyzing SIB data, the Columbia Classification Algorithm for Suicide Assessment (C-CASA). For new drugs undergoing clinical development, assessment of SIB is incorporated into benefit/risk decision-making and continuing risk management approaches throughout the pharmaceutical industry and academia. A number of companies have developed internal guidances, which may include quantitative decision-criteria (i.e., based on binding data at CNS targets) or qualitative clinical judgment (i.e., based on mechanistic understanding and emerging safety profiles) of drug candidates that may require the inclusion of prospective SIB tools. In this chapter, we will provide an overview of the regulatory history surrounding treatment emergent SIB and will outline a number of structured qualitative steps for prospective SIB assessment.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alexopoulos GA, Abrams RC, Young RC, Shamoian CA (1988) Cornell Scale for depression in Dementia. Biol Psychiatry 23:271–284
Andersohn F, Schade R, Willich SN, Garge E (2010) Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior. Neurology 75:335–340
Arana A, Wentworth CE, Ayuso-Mateos JL, Arellano FM (2010) Suicide-related events in patients treated with antiepileptic drugs. N Engl J Med 363:542–551
Bartels SJ, Coakley E, Oxman TE, Constantino G, Oslin D, Chen H, Zubritsky C, Cheal K, Durai UN, Gallo JJ, Llorente M, Sanchez H (2002) Suicidal and death ideation in older primary care patients with depression, anxiety and at-risk alcohol use. Am J Geriatric Psychiatry 10:417–427
Brent DA, Mann JJ (2005) Family genetic studies, suicide, and suicidal behavior. Am J Med Genet C 133:13–24
Brent D, Melhem N, Turecki G (2010) Pharmacogenomics of suicidal events. Pharmacogenomics 11:793–807
Cavanagh JT, Carson AJ, Sharpe M, Lawrie SM (2003) Psychological autopsy studies of suicide: a systematic review. Psychol Med 33(3):395–405
Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44(12):2308–2314
Cummings JL (1997) The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 48(5 Suppl 6):S10–S16
FDA (2008) Statistical review and evaluation: anti-epileptic drugs and suicidality. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-01-FDA.pdf
Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, Hutton B (2005) Association between suicide attempts and selective serotonin reuptake inhibitors; systematic review of randomised controlled trials. BMJ 330(7488):396
Fergusson DM, Woodward IJ, Horwood IJ (2000) Risk factors and life processes associated with the onset of suicidal behavior during adolescence and early adulthood. Psychol Med 30(1):23–29
Gassman-Meyer C, Jiang K, McSorley P, Arani R, DuBrava S, Suryawanshi S, Webb DM, Nilsson M (2011) Clinical and statistical assessment of suicidal ideation and behavior in pharmaceutical trials. Clin Pharmacol Therapeutics 90(4):554–560
Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA, Herings RM, Mann JJ (2007) Early evidence of the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 164(9):1356–1363
Gibbons RD, Hur K, Brown CH, Mann JJ (2009) Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder. Arch Gen Psychiatry 66:1354–1360
Gibbons RD, Hur K, Bhaumik DK, Mann JJ (2006) The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry 163(11):1898–1904
Goodwin F, Jamison K (2007) Manic–depressive illness: Bipolar disorders and recurrent depression. 2nd edn. Oxford University Press, Oxford, England
Hammad TA, Laughren T, Racoosin J (2006) Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 63(3):332–339
Institute of Medicine (IOM) (2010) CNS clinical trials: suicidality and data collection. In: Workshop summary. The National Academies Press, Washington DC
Kaufer DI, Cummings JL, Christine D, Bray T, Castellon S, Masterman D, MacMillan A, Ketchel P, Dekosky ST (1998) Assessing the impact of neuropsychiatric symptoms in Alzheimer’s Disease: the neuropsychiatric inventory caregiver distress scale. J Am Geriatric Soc 46:210–215
Kroenke K, Spitzer RL (2002) The PHQ-9: a new depression diagnostic and severity measure. Psychiatric Ann 32:509–515
Laje G, Allen AS, Akula N, Manji H, John Rush A, McMahon FJ (2009) Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. Pharmacogenet Genomics 19:666–674
Libby AM, Orton HD, Valuck RJ (2009) Persisting decline in depression treatment after FDA warnings. Arch Gen Psychiatry 66:633–639
Medicines and Healthcare Products Regulatory Agency (2003) Selective serotonin reuptake inhibitor—use in children and adolescents with major depressive disorder. http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con019492.pdf
Menke A, Domschke K, Czamara D, Klengel T, Hennings J, Lucae S, Baune BT, Arolt V, Muller-Myschok B, Holsboer F, Binder EB (2012) Genome-wide association study of antidepressant treatment-emergent suicidal ideation. Neuropsychopharmacology 37:797–807
Nierenberg AA, Trivedi MH, Ritz L, Burroughs D, Greist J, Sackeim H, Kornstein S, Schwartz T, Stegman D, Fava M, Wisniewski SR (2004) Suicide risk management for the sequenced treatment alternatives to relieve depression study: applied NIMH guidelines. J Psychiatric Res 38(6):583–589
Nock MK, Hwang I, Sampson N, Kessler RC, Angermeyer M, Beautrais A, Borges G, Bromet E, Bruffaerts R, de Girolamo G, de Graaf R, Florescu S, Gureje O, Haro JM, Hu C, Huang Y, Karam EG, Kawakami N, Kovess V, Levinson D, Posada-Villa J, Sagar R, Tomov T, Viana MC, Williams DR (2009a) Cross-national analysis of the associations among mental disorders and suicidal behavior: Findings from the WHO world mental health surveys. PLoS Med 6(8):e1000123
Nock MK, Hwang I, Sampson NA, Kessler RC. (2009b). Mental disorders, comorbidity and suicidal behavior: Results from the National Comorbidity Survey Replication. Mol Psychiatry (31 March 2009)
Olesen JB, Hansen PR, Erdal J, Abildstrøm SZ, Weeke P, Fosbøl EL, Poulsen HE, Gilason GH (2010) Antiepileptic drugs and risk of suicide: a nationwide study. Pharmacoepidemiol. Drug Safety 19:518–524
Olfson M, Shaffer D, Marcus SC, Greenberg T (2003) Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 60(10):978–982
Osman A, Bagge CL, Gutierrez PM, Konick LC, Kopper BA et al (2001) The suicidal behaviors questionnaire-revised (SBQ-R): validation with clinical and nonclinical samples. Assessment 8(4):443–454
Patorno E, Bohn RL, Wahl PM, Avorn J, Patrick AR, Liu J, Schneeweiss S (2010) Anticonvulsant medications and the risk of suicide, attempted suicide or violent death. JAMA 303:1401–1409
Perroud N (2011) Suicidal ideation during antidepressant treatment: do genetic predictors exist? CNS Drugs 25:459–471
Perroud N, Uher R, Ng MY, Guipponi M, Hauser J, Henigsberg N et al (2012) Genome–wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project. Pharmacogenomics 12(1):68–77
Pompili M, Baldessarini RJ (2010) Risk of suicidal behavior with antiepileptic drugs. Nature Rev Neurol 6:651–653
Pompili M, Tatarelli R (eds) (2010) Evidence-based practice in suicidology: a sourcebook. Hogrefe, Gottingen
Pompili M, Tatarelli R, Girardi P, Tondo L, Baldessarini RJ (2010) Suicide risk during anticonvulsant treatment. Pharmacoepidemiol Drug Safety 19:525–528
Posner K (2009) C-CASA and C-SSRS in CNS clinical trials: development and implementation. In: Presentation at the IOM workshop on CNS clinical trials: suicidality and data collection, Washington DC, June 16
Reynolds WM (1987) Suicidal ideation questionnaire (SIQ): professional manual. Psychological Assessment Resources, Odessa
Reynolds WM, Mazza JJ (1999) Assessment of suicidal ideation in inner-city children and young adolescents: reliability and validity of the suicidal ideation questionnaire-Jr. Sch Psychol Rev 28:17–30
Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB (2003) The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54:573–583
Sareen J, Cox BJ, Afifi TO, de Graaf R, Asmundson GJ, ten Have M, Stein MB (2005) Anxiety disorders and risk for suicidal ideation and suicide attempts: a population based longitudinal study of adults. Arch Gen Psychiatry 62(11):1249–1257
Simon GE (2006) How can we know whether antidepressants increase suicide risk? Am J Psychiatry 163(11):1861–1863
Sondergard I, Kvist K, Andersen PK, Kessing LV (2006) Do antidepressants precipitate youth suicide?: a nationwide pharmacoepidemiological study. Eur Child Adolesc Psychiatry 15(4):232–240
Statham DJ, Heath AC, Madden PA, Buchholz KK, Bierut L, Dinwiddie SH, Martin NG (1998) Suicidal behaviour: an epidemiological and genetic study. Psychol Med 28:839–855
Stone M, Laughren T, Jones L, Levenson M, Holland PC, Hughes A, Hammad TA, Temple R, Rochester G (2009) Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US food and drug administration. BMJ 339:b2880
Szanto K, Mulsant BH, Houck P, Drew MA, Reynolds CF 3rd (2003) Occurrence and course of suicidality during short-term Treatment of late-life depression. Arch Gen Psychiatry 60(6):610–617
Valuck RJ, Libby AM, Orton HD, Morrato EH, Allen R, Baldessarini RJ (2007) Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRI’s. Am J Psychiatry 164(8):1198–1205
Van Cott AC, Cramer JA, Copeland LA, Zeber JE, Steinman MA, Dersh JJ, Glickman ME, Mortensen EM, Amuan ME, Pugh MJ (2010) Suicide-related behaviors in older patients with new anti-epileptic drug use: data from the VA hospital system. BMC Med 8:4–11
Wood S, Cummings JL, Hsu M-A, Barclay T, Wheatley MV, Yarema KT, Schnelle JE (1999) The use of the neuropsychiatric inventory in nursing home residents: characterization and measurement. Am J Geriatric Psychiatry 8:75–83
Acknowledgements
The authors would like to acknowledge additional members of the Suicidal Ideation and Behavior Working Group [Michelle Stewart, Sarah Dubrava, Donna Palumbo, Susan Anway, Nathan Chen, Brendon Binneman, Keri Cannon, Deborah Light and Douglas Kalunian (now at Group Health Permanente), Douglas Feltner (now at AbbVie)] for their contributions to internal and cross-industry guidance on SIB assessment in clinical trials.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Ratcliffe, S.L., Chappell, P.B., Boyce-Rustay, J., Gloukhova, S., Oleske, D.M. (2014). Treatment Emergent Suicidal Ideation and Behavior. In: Cannon, K., Hudzik, T. (eds) Suicide: Phenomenology and Neurobiology. Springer, Cham. https://doi.org/10.1007/978-3-319-09964-4_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-09964-4_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-09963-7
Online ISBN: 978-3-319-09964-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)